---
title: 'PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0):
  a report of the RANO group'
date: '2024-01-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38181810/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240106170748&v=2.18.0
source: heidelberg[Affiliation]
description: Response Assessment in Neuro-Oncology (RANO) response criteria have been
  established and were updated in 2023 for MRI-based response evaluation of diffuse
  gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers
  is increasingly considered for disease monitoring in both clinical practice and
  clinical trials. So far, a standardised framework defining timepoints for baseline
  and follow-up investigations and response evaluation criteria for PET imaging of
  diffuse ...
disable_comments: true
---
Response Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse ...